Company: BGLC
Filing Date: 2025-11-07
Form Type: S-3
Source: 0001477932-25-007976
Chunk: 16

Company: BioNexus Gene Lab Corp
Filing Date: 2025-11-07
Form: S-3
Chunk 16
---
 thresholds). If applicable, the acquiring person obtains voting rights in the acquired “control shares” only if approved by the shareholders as provided by statute. A corporation may opt out of these provisions in its charter or bylaws; our Articles of Incorporation and Bylaws do not contain an opt-out. These provisions, if applicable, could deter or delay certain change-in-control transactions.

Business Combinations with Interested Stockholders (Wyoming Management Stability Act, §17-18-104)

Wyoming also restricts certain business combinations between a “qualified corporation” and an “interested stockholder” (generally, a person owning 15% or more of the outstanding voting stock) for three years after the time the person becomes an interested stockholder, unless certain approvals are obtained or an exception applies. Corporations may elect not to be subject to these restrictions in their charter, bylaws, or by filing a statement with the Wyoming Secretary of State. Our Articles of Incorporation and Bylaws do not contain an election to opt out of these restrictions. These provisions may have the effect of delaying, deferring, or preventing a change in control.

Preferred Stock Designation

In February 2025, the Company filed Articles of Amendment designating one share of “Series Z” preferred stock (since utilized in connection with a shareholder vote process). The board’s authority to designate preferred stock—including the Series Z designation—illustrates the flexibility to issue preferred shares with rights that could, among other things, delay or prevent a change of control.

| 9 |

<div align='center'>DESCRIPTION OF WARRANTS</div>

The following is a general description of the terms of the warrants we may issue from time to time. Particular terms of any warrants we offer will be described in the prospectus supplement relating to such warrants, as well as any warrant agreement that contains the terms of the warrants. We urge you to read the applicable prospectus supplements related to the warrants that we may sell under this prospectus, as well as the complete warrant agreements that will contain the terms of any warrants.

We may issue warrants to purchase shares of our common stock or preferred stock. Such warrants may be issued in one or more series, independently or together with shares of common stock or preferred stock or other equity or debt securities and may be attached or separate from such securities. The warrants may also be in the form of pre-funded warrants. The terms of any warrants offered under a prospectus supplement may differ from the terms described below. We may issue warrants directly or under a separate warrant agreement